Treatment of Adolescent Depression

Initial Treatment Approach

The American Academy of Pediatrics recommends beginning with a period of active support and monitoring (6-8 weeks) before initiating formal evidence-based treatment for adolescents with mild depression 2, 3, 1
Psychotherapy, specifically cognitive-behavioral therapy (CBT) or interpersonal psychotherapy for adolescents (IPT-A), is the first-line treatment for adolescents with mild to moderate depression, with a recommended initiation after the monitoring period if symptoms persist 1
Incorporate lifestyle interventions, including structured physical exercise, sleep hygiene optimization, and adequate nutrition, as foundational elements of treatment 1, 4

For moderate to severe cases, initiate treatment immediately without a monitoring period, and consider consulting with a mental health specialist if complicating factors are present 5, 2, 3
Psychotherapy (CBT or IPT-A) remains the preferred initial approach for moderate depression, with consideration of medication (fluoxetine) when psychotherapy alone is insufficient or when rapid response is clinically necessary 1, 4

Interpersonal psychotherapy for adolescents (IPT-A) demonstrates significant superiority over treatment as usual in reducing depression severity, suicidal ideation, and hopelessness, particularly in adolescents with higher baseline interpersonal difficulties 5, 2, 1
Cognitive-behavioral therapy (CBT) has an estimated effect size of 1.27 in treating adolescent depression, although CBT monotherapy showed only a 43.2% response rate compared to 34.8% for placebo in the landmark Treatment of Adolescent Depression Study (TADS) 2, 3

Fluoxetine is the only FDA-approved antidepressant for children and adolescents with depression (ages 8-18), with a recommended starting dose of 10 mg daily and effective dose typically 20 mg daily 4, 1
Combined fluoxetine plus CBT achieved a 71% response rate versus 35% for placebo in TADS, significantly superior to either treatment alone 4
Avoid duloxetine, venlafaxine, and paroxetine as first-line choices due to higher rates of intolerable side effects 3, 1

Assess patients in person within 1 week of treatment initiation and regularly thereafter to monitor for suicidal thinking and behavior, as well as common adverse effects such as nausea, headaches, and behavioral activation 4, 2, 3
Slowly taper all SSRIs when discontinued to prevent withdrawal effects, and do not conclude treatment is ineffective before completing an adequate trial: 8 weeks at optimal dosage for antidepressants 4, 1